ATM and TGFB1 polymorphism in prediction of late complications of chemoreadiotherapy in patients with locally advanced cervical cancer

Cervical cancer is due to high incidence the third most commonly diagnosed gynecological cancer in the Czech republic. More than 50% of these tumors are diagnosed in advanced stage (st. IIB and higher) and therapy is more difficult than in lower stage tumors. The standard treatement method for locally advanced cervical cancers is combined oncological therapy including external beam radiotherapy, brachytherapy and concomitant chemotherapy. This treatement provides good tumor control, but there is also a risk of late complications in irradiated area. Severe late complications affect 10-15% of patients. It is still not possible to predict late complications and therefore detection of valid predictive factors for high tissue radiosensitivity could help to identify patients with increased risk before therapy. Knowledge of such predictive factors would also help to individualize the treatement. New molecular biological methods brought new findings about cancerogenesis, cell cycle regulation and cellular reaction to the radiation damage. It was hypothized, that mutation of genes involved in DNA damage reparation or cell proliferation are one of causes of high tissue radiosensitivity. The aim of our study was to evaluate relations between ATM and TGFß1 polymorphisms and late tissue toxicity in patients treated for..